Royalty Pharma plc

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net Income $42.8m $1.1b $859.0m $770.9m
Net Income From Continuing Operations $230.1m $1.7b $1.3b $1.3b
Amortization Cash Flow $23.0m $5.7m $0 $0
Amortization Of Intangibles $23.0m $5.7m $0 $0
Depreciation $0 $0 $3.9m
Depreciation Amortization Depletion $5.7m $0 $0 $3.9m
Asset Impairment Charge $0 $615.8m $0 $0
Distributions from equity method investees $39.4m $14.1m $42.3m $34.4m $0 $43.9m $23.6m $105.1m
Investments in equity method investees ($24.2m) ($27.0m) ($40.2m) ($34.9m) ($9.9m) ($12.5m) ($11.0m) $0
Earnings (Loss)es From Equity Investments $9.0m ($28.9m) ($29.6m) ($29.1m)
Cash collections from financial royalty assets $2.1b $1.9b $2.1b $2.3b $2.5b $3.2b $3.0b $3.4b
Cash collections from intangible royalty assets $106.7m $143.3m $143.8m $151.2m $72.9m $1.3m $14.6m $720k
Other royalty cash collections $125.2m $27.4m $18.3m $44.1m $69.9m $158.8m $108.8m $114.0m
Interest received $24.4m $20.1m $7.7m $3.1m $25.0m $71.6m $46.5m $34.3m
Development-stage funding payments ($52.0m) ($2.0m) ($452.0m)
Payments for operating and professional costs ($72.5m) ($88.5m) ($179.7m) ($184.5m) ($223.0m) ($243.0m) ($236.2m) ($288.1m)
Payments for Employee EPAs $0 $0 ($10.9m)
Purchases of equity securities ($152.8m) ($79.0m) ($50.0m) ($135.1m) ($87.8m) $0 ($62.5m) ($58.4m)
Proceeds from equity securities $0 $0 $384.8m $116.0m $211.2m $0 $98.6m $34.7m
Purchases of available for sale debt securities $0 ($125.1m) $0 ($70.4m) ($479.6m) $0 ($150.0m) ($175.0m)
Proceeds from sales and maturities of marketable securities $0 $725.1m $815.4m $1.6b $792.3m $24.4m $0 $0
Acquisitions of financial royalty assets ($269.6m) ($1.7b) ($2.2b) ($2.2b) ($1.7b) ($2.1b) ($2.5b) ($1.7b)
Acquisitions of other financial assets $0 $0 ($21.2m) $0 ($18.0m) $0
Milestone payments $0 ($250.0m) $0 ($18.6m) $0 ($12.4m) ($75.0m) ($271.3m)
Other $0 $0 ($2.0m) ($9.0m) ($1.8m)
Distributions to legacy non-controlling interests - Portfolio Receipts ($479.6m) ($442.0m) ($377.0m) ($362.3m) ($354.9m)
Distributions to continuing non-controlling interests ($268.7m) ($154.1m) ($544.0m) ($479.6m) ($144.1m) ($119.5m) ($125.2m) ($167.5m)
Repurchases of Class A ordinary shares $0 ($4.3m) $0 $0 $0 ($304.8m) ($229.7m) ($1.2b)
Contributions from legacy non-controlling interests - R&D $0 $0 $8.5m $7.3m $1.1m $543k $747k $220k
Contributions from non-controlling interests - other $0 $0 $59.0m $36.9m $6.1m $6.9m $4.4m $5.7m
Cash acquired in connection with purchase of non-controlling interest $0 $0 $5.0m $0 $0
Proceeds from revolving credit facility $0 $0 $350.0m $0 $1.3b
Repayment of revolving credit facility $0 $0 ($350.0m) $0 ($1.3b)
Beginning Cash Position $1.5b $1.7b $477.0m $929.0m
Cash Flow From Continuing Financing Activities ($944.9m) ($2.1b) $361.1m ($1.2b)
Cash Flow From Continuing Investing Activities ($1.0b) ($2.1b) ($2.7b) ($1.6b)
Change In Account Payable $2.3m $6.2m ($2.3m) ($13.9m)
Change In Accrued Expense ($3.5m) ($2.5m) $46.4m $8.9m
Change In Interest Payable ($3.5m) ($2.5m) $46.4m $8.9m
Change In Other Current Assets $38.7m $3.1m $13.8m ($7.4m)
Change In Other Current Liabilities $0 $0 ($2.4m)
Change In Payable $2.3m $6.2m ($2.3m) ($13.9m)
Change In Payables And Accrued Expense ($1.2m) $3.8m $44.1m ($5.0m)
Change In Receivables ($4.7m) ($1.5m) ($4.6m) ($2.4m)
Change In Working Capital $32.7m $5.4m $53.4m ($17.2m)
Changes In Cash $169.7m ($1.2b) $452.0m ($310.3m)
End Cash Position $1.7b $477.0m $929.0m $618.7m
Financing Cash Flow ($944.9m) ($2.1b) $361.1m ($1.2b)
Free Cash Flow $2.1b $3.0b $2.8b $2.5b
Gain Loss On Investment Securities ($2.2b) ($2.5b) ($2.3b) ($2.3b)
Investing Cash Flow ($1.0b) ($2.1b) ($2.7b) ($1.6b)
Issuance Of Capital Stock $0 $0
Net Business Purchase And Sale ($9.9m) ($12.5m) ($11.0m) ($74.4m)
Operating Gains Losses ($2.2b) ($2.5b) ($2.4b) ($2.3b)
Other Non Cash Items $2.5b $3.2b $3.0b $3.4b
Provisionand Write Offof Assets $904.2m $560.7m $732.5m ($206.8m)
Purchase Of Business ($9.9m) ($12.5m) ($11.0m) ($74.4m)
Repurchase Of Capital Stock $0 ($304.8m) ($229.7m) ($1.2b)
Stock Based Compensation $2.2m $2.4m $2.3m $289.9m
Net cash provided by operating activities $1.6b $1.7b $2.0b $2.0b $2.1b $3.0b $2.8b $2.5b
Acquisition of businesses, net of cash acquired $0 $0 ($74.4m)
Net Investment Purchase And Sale ($1.0b) ($2.1b) ($2.6b) ($1.4b)
Purchase Of Investment ($2.6b) ($2.1b) ($2.7b) ($1.9b)
Sale Of Investment $1.5b $25.8m $118.4m $566.5m
Net Other Investing Changes ($18.6m) ($14.4m) ($73.0m) ($280.3m)
Net cash used in investing activities $303.4m ($2.2b) ($2.8b) ($1.9b) ($1.0b) ($2.1b) ($2.7b) ($1.6b)
Proceeds from available for sale debt securities $750.0m $150.0m $3.0m $62.5m $542.0m $1.4m $19.8m $21.2m
Proceeds from sales of available for sale debt securities $0 $0 $510.6m
Proceeds from issuance of long-term debt, net of discount $0 $11.9b $1.3b $0 $0 $1.5b $2.0b
Debt issuance costs and other ($2.0m) $0 ($46.7m) ($13.0m) ($1.3m) ($1.6m) ($12.6m) ($16.6m)
Issuance Of Debt $0 $350.0m $1.5b $3.2b
Long Term Debt Issuance $0 $350.0m $1.5b $3.2b
Net Issuance Payments Of Debt $0 ($1.0b) $1.5b $954.5m
Net Long Term Debt Issuance $0 ($1.0b) $1.5b $954.5m
Net Short Term Debt Issuance $0 $0 $0
Short Term Debt Issuance $0 $0 $350.0m
Repayment of long-term debt $0 $0 ($1.0b) $0 ($1.0b)
Long Term Debt Payments $0 ($1.4b) $0 ($2.3b)
Repayment Of Debt $0 ($1.4b) $0 ($2.3b)
Short Term Debt Payments $0 $0 ($350.0m)
Common Stock Issuance $0 $0
Net Common Stock Issuance $0 ($304.8m) ($229.7m) ($1.2b)
Common Stock Payments $0 ($304.8m) ($229.7m) ($1.2b)
Dividends to shareholders $0 $0 ($112.5m) ($285.2m) ($333.3m) ($358.3m) ($376.5m) ($378.3m)
Cash Dividends Paid ($333.3m) ($358.3m) ($376.5m) ($378.3m)
Common Stock Dividend Paid ($333.3m) ($358.3m) ($376.5m) ($378.3m)
Dividend Received CFO $39.1m $18.8m $13.4m $13.4m
Dividends Received CFI $0 $43.9m $23.6m $105.1m
Net Other Financing Charges ($611.5m) ($485.7m) ($504.0m) ($534.8m)
Net cash (used in)/provided by financing activities ($1.4b) ($1.2b) $1.5b $385.1m ($944.9m) ($2.1b) $361.1m ($1.2b)
Net change in cash and cash equivalents $542.6m ($1.7b) $762.5m $532.4m $169.7m ($1.2b) $452.0m ($310.3m)
Cash and cash equivalents, beginning of period $1.9b $246.2m $1.0b $1.5b $1.7b $477.0m $929.0m $618.7m
Change In Cash Supplemental As Reported $169.7m ($1.2b) $452.0m ($310.3m)
Interest paid ($267.7m) ($255.0m) ($103.2m) ($130.4m) ($170.1m) ($169.2m) ($159.6m) ($276.3m)

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.